Cargando…

Antibody engineering to develop new antirheumatic therapies

There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immuno-suppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment...

Descripción completa

Detalles Bibliográficos
Autor principal: Isaacs, John D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714093/
https://www.ncbi.nlm.nih.gov/pubmed/19490600
http://dx.doi.org/10.1186/ar2594
_version_ 1782169634026291200
author Isaacs, John D
author_facet Isaacs, John D
author_sort Isaacs, John D
collection PubMed
description There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immuno-suppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment, with many more patients achieving disease remission. There is even a prevailing sense that disease 'cure' may be a realistic goal in the future. These developments were underpinned by an earlier revolution in molecular biology and protein engineering as well as key advances in our understanding of rheumatoid arthritis pathogenesis. This review will focus on antibody engineering as the key driver behind our current and developing range of antirheumatic treatments.
format Text
id pubmed-2714093
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27140932009-11-19 Antibody engineering to develop new antirheumatic therapies Isaacs, John D Arthritis Res Ther Review There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immuno-suppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment, with many more patients achieving disease remission. There is even a prevailing sense that disease 'cure' may be a realistic goal in the future. These developments were underpinned by an earlier revolution in molecular biology and protein engineering as well as key advances in our understanding of rheumatoid arthritis pathogenesis. This review will focus on antibody engineering as the key driver behind our current and developing range of antirheumatic treatments. BioMed Central 2009 2009-05-19 /pmc/articles/PMC2714093/ /pubmed/19490600 http://dx.doi.org/10.1186/ar2594 Text en Copyright © 2009 BioMed Central Ltd
spellingShingle Review
Isaacs, John D
Antibody engineering to develop new antirheumatic therapies
title Antibody engineering to develop new antirheumatic therapies
title_full Antibody engineering to develop new antirheumatic therapies
title_fullStr Antibody engineering to develop new antirheumatic therapies
title_full_unstemmed Antibody engineering to develop new antirheumatic therapies
title_short Antibody engineering to develop new antirheumatic therapies
title_sort antibody engineering to develop new antirheumatic therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714093/
https://www.ncbi.nlm.nih.gov/pubmed/19490600
http://dx.doi.org/10.1186/ar2594
work_keys_str_mv AT isaacsjohnd antibodyengineeringtodevelopnewantirheumatictherapies